Trial
NCT03486067
Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Multiple Myeloma
Intervention
CC-93269
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-17